Jenna Fernandez
About Jenna Fernandez
Jenna Fernandez is a scientist specializing in IO and gene editing in cell therapy at Bristol Myers Squibb, with a background in developing non-viral delivery methods for CAR-T cell applications.
Current Title and Role
Jenna Fernandez holds the position of Scientist, IO and Gene Editing in Cell Therapy at Bristol Myers Squibb. In her current role, she focuses on advancing gene editing technologies and immuno-oncology approaches to improve cell therapy treatments. Her responsibilities include the development of innovative tools and assays specifically for non-viral delivery methods in CAR-T cell applications.
Previous Experience at Juno Therapeutics
Prior to her current role, Jenna Fernandez was an Associate Scientist at Juno Therapeutics, Inc., where she worked from 2016 to 2021 in Seattle, Washington. During her five-year tenure, she gained extensive experience in IO and gene editing in cell therapy. Her work primarily involved using CRISPR technology for clinical gene editing platforms and contributing to advancements in viral vector engineering and production.
Research Experience at University of Washington
Jenna Fernandez served as an Assistant Research Scientist at the University of Washington from 2014 to 2016. She was part of the Department of Pathology, where she conducted research on T-cell engineering and tissue culture. Her work involved utilizing flow cytometry and various molecular biology techniques to enhance the understanding and applications of cellular processes.
Educational Background
Jenna Fernandez completed her Bachelor's Degree in Molecular, Cellular, and Developmental Biology at the University of Washington from 2012 to 2015. Her academic background provided a strong foundation in the principles of molecular biology, cellular processes, and developmental systems, which she applies in her scientific research and professional endeavors.
Technical Skills and Expertise
Jenna Fernandez possesses expertise in a range of technical skills relevant to her field. She is skilled in T-cell engineering, viral vector engineering, and production. Her technical proficiency extends to non-viral delivery methods for CAR-T cell applications and the use of CRISPR technology for gene editing. Additionally, she is experienced in tissue culture, flow cytometry, and various molecular biology techniques.